MarkTechPost Features Verseon’s CEO in AI in Healthcare Issue

“The current state of AI in drug discovery strongly resembles the dot com boom of the late 1990s. Many companies simply use AI as a buzzword … Such companies will see their prominence in the drug discovery space wane over time.

“We’ve spent a decade and a half developing fundamental advancements in computational chemistry, molecular-physics modeling, and applications of AI to make systematic design of completely new drug molecules a reality.

“… our ability to explore uncharted chemical space allows us to find drug candidates with uniquely desirable properties for the treatment of every disease we address.”